Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2010, Article ID 938408, 6 pages
http://dx.doi.org/10.1155/2010/938408
Clinical Study

Elevated Adiponectin Serum Levels in Women with Systemic Autoimmune Diseases

1Department of Rheumatology, University Hospital Jean Minjoz, Bd Fleming, 25030 Besançon Cedex, France
2University Hospital St Jacques, CIC Biotherapy-CBT 506, 25030 Besançon Cedex, France
3University of Franche Comté, Équipe d'Accueil 4266 “Agents Pathogènes et Inflammation”, IFR133, 25000 Besançon, France
4INSERM UMR645, 1 Bd A Fleming, 25020 Besançon Cedex, France
5University of Franche-Comté, UMR645, IFR133, 25020 Besançon Cedex, France
6EFS Bourgogne Franche-Comté, Plateforme de Biomonitoring, 25020 Besançon Cedex, France
7Department of Physiology, University Hospital Jean Minjoz, Bd Fleming, 25030 Besançon Cedex, France
8University of Franche Comté, Équipe d'Accueil EA 3920 “Physiopathologie Cardiovasculaire et Prévention”, IFR133, 25000 Besançon, France

Received 20 April 2010; Revised 14 September 2010; Accepted 7 November 2010

Academic Editor: Oreste Gualillo

Copyright © 2010 Éric Toussirot et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Adipose tissue produces a wide range of proteins that may influence the immune system. In this study, we assessed the serum levels of leptin, adiponectin, and ghrelin, in association with the measurements of body composition, in 15 female patients with various autoimmune diseases (systemic lupus erythematosus, primary Sjögren's syndrome, sarcoidosis, mixed connective tissue disease, vasculitis, CREST syndrome, and polymyositis) and in 15 healthy female controls. There were no statistically significant differences between the patients and controls with regard to serum leptin, serum ghrelin, global fat mass, adiposity, and fat mass in the android or gynoid regions, whereas serum adiponectin levels were higher in patients than controls ( 1 6 . 3 ± 1 . 6 μg/mL versus 9 . 7 ± 0 . 6 μg/mL; 𝑃 = . 0 1 ). As adiponectin is known to exhibit potent anti-inflammatory properties, a high adiponectinemia in patients with systemic autoimmune disease may mitigate the inflammatory response. However, the precise consequences of these elevated serum adiponectin levels on the metabolic syndrome development and atherosclerotic cardiovascular risk in this patient population still needs to be determined.